Abstract
In the context of metabolic reprogramming of tumor cells (Warburg effect), several proteins show an increased expression, including monocarboxylate transporters (MCTs). Recently, MCT1 was identified as a major determinant of the sensitivity to 3-bromopyruvate (3-BP), one of the most promising inhibitors of glycolytic metabolism. So, in addition to a potential therapeutic target, MCT1 aris…